Journal: Experimental Hematology & Oncology

Article Title: High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

doi: 10.1186/s40164-024-00524-4

Figure Lengend Snippet: The impact of huCD8 + T cell depletion on the efficacy of huCD20-Fc-AFN. A Demonstration of huCD8 + T cell depletion by flowcytometry. Depletion was performed by OKT8 administration IP 2x/week (week 1: 200 μg/week 2–3-4: 100 μg) starting 2 days prior to start of treatments. Complete huCD8 + T cell depletion in the blood was confirmed prior to last depletion. Demonstration of near complete huCD8 + T cell depletion in blood, bone marrow, spleen, and PDX tumor up to 22 from last OKT-8 administration in combination with PBS or huCD20-Fc-AFN. No significant differences in total huCD3 + T cell counts were observed, indicating the selective huCD8 depletion by OKT-8 administration. B Tumor volumes and Kaplan Meier survival curves from tumor inoculation in HIS NSG (n = 13–14/group). Administration of huCD20-Fc-AFN 40μg 1x/week for 4 weeks from D13. PDX characteristics can be found in Table and Table for specific experimental conditions. HIS : human immune system; HR : Hazard Ratio; PBS : Phosphate-buffered saline; AFN: AcTaferon

Article Snippet: For huCD8 depletion, InVivoMAbTM anti-human CD8α (#BE0004-2, clone OKT8, Bio X Cell) was administered 2x/week IP for 4 weeks (200 μg W1; 100 μg W2–3–4), starting D-2.

Techniques: Saline

Journal: Experimental Hematology & Oncology

Article Title: High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

doi: 10.1186/s40164-024-00524-4

Figure Lengend Snippet: In vivo experimental setup

Article Snippet: For huCD8 depletion, InVivoMAbTM anti-human CD8α (#BE0004-2, clone OKT8, Bio X Cell) was administered 2x/week IP for 4 weeks (200 μg W1; 100 μg W2–3–4), starting D-2.

Techniques: In Vivo, Injection

Journal: Experimental Hematology & Oncology

Article Title: High efficacy of huCD20-targeted AcTaferon in humanized patient derived xenograft models of aggressive B cell lymphoma

doi: 10.1186/s40164-024-00524-4

Figure Lengend Snippet: Schematic overview of humanized PDX generation and experimental setup. Newborn NSG mice are humanized using CD34 + MACS selected HSC derived from umbilical cord bloods, engraftment was checked by flow cytometry. Humanized mice were inoculated with early-passage PDX tumors freshly isolated from non-humanized NSG mice. Intravenous treatments were started at fixed timepoints or tumor size, optionally preceded by intraperitoneal huCD8 depletion or huDC stimulation. See text for further details, PDX characteristics can be found in Table and Table for specific experimental conditions. MACS : Magnetic-activated cell sorting; NSG : NOD scid gamma; IH : intrahepatic; cGy : centigray; IV : intravenous; xGVHD : xenogeneic graft-versus-host-disease; huDC : human dendritic cells; PK/PD : pharmacokinetics/dynamics; CB : Cord blood

Article Snippet: For huCD8 depletion, InVivoMAbTM anti-human CD8α (#BE0004-2, clone OKT8, Bio X Cell) was administered 2x/week IP for 4 weeks (200 μg W1; 100 μg W2–3–4), starting D-2.

Techniques: Derivative Assay, Flow Cytometry, Isolation, FACS, Drug discovery